Immunohistochemical analysis of EZH2 performed on tumor samples of 360 patients with stage IIIB and IV non-small cell lung cancer who received platinum-based chemotherapy continuously showed that patients with advanced non-small cell lung cancer with EZH2 positive expression showed resistance to cisplatin-based chemotherapy.85 This evidence concerns the gene EZH2 and non-small cell lung carcinoma.